Novo Nordisk (NVO) is aimed at dominating the GLP-1 market News ad

Novo Nordisk (NVO) is aimed at dominating the GLP-1 market

 News ad

Novo Nordisk a/s. NYSE: NVO He announced that his GLP-1 drugs in chronic obesity, with Ozempic and Wegovy brands, are no longer in deficiency. This led to the fact that the United States Products and Medications Office took half -Glutid, an active ingredient in both, from a list of drug lack of drugs on February … Read more

MASH approval could revive GLP-1 sales News ad

MASH approval could revive GLP-1 sales

 News ad

Novo Nordisk A/S today NGO Novo Nordisk A/S $107.93 -0.08 (-0.07%) (As of 12:16 pm ET) 52 week range $99.42 ▼ US$148.15 Dividend yield 0.67% P/E ratio 34.93 Target price US$150.40 Recent sales of little-known Madrigal Pharmaceuticals stock. NASDAQ: MDGLcould bode well for Novo Nordisk A/S New York Stock Exchange: HBO. The pharmaceutical giant has … Read more